TY  - JOUR
AU  - Morbelli, Silvia
AU  - Esposito, Giuseppe
AU  - Arbizu, Javier
AU  - Barthel, Henryk
AU  - Boellaard, Ronald
AU  - Bohnen, Nico I.
AU  - Brooks, David J
AU  - Darcourt, Jacques
AU  - Dickson, John C.
AU  - Douglas, David
AU  - Drzezga, Alexander
AU  - Dubroff, Jacob
AU  - Ekmekcioglu, Ozgul
AU  - Garibotto, Valentina
AU  - Herscovitch, Peter
AU  - Kuo, Phillip
AU  - Lammertsma, Adriaan
AU  - Pappata, Sabina
AU  - Peñuelas, Iván
AU  - Seibyl, John
AU  - Semah, Franck
AU  - Tossici-Bolt, Livia
AU  - Van de Giessen, Elsmarieke
AU  - Van Laere, Koen
AU  - Varrone, Andrea
AU  - Wanner, Michele
AU  - Zubal, George
AU  - Law, Ian
TI  - EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
JO  - European journal of nuclear medicine and molecular imaging
VL  - 47
IS  - 8
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - FZJ-2021-00063
SP  - 1885 - 1912
PY  - 2020
AB  - PurposeThis joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.MethodsCurrently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.ConclusionAll these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
LB  - PUB:(DE-HGF)16
C6  - 32388612
UR  - <Go to ISI:>//WOS:000531214000004
DO  - DOI:10.1007/s00259-020-04817-8
UR  - https://juser.fz-juelich.de/record/889138
ER  -